121 related articles for article (PubMed ID: 11776376)
1. Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma.
Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Ichiyama M; Tsumoto K; Asano R; Kumagai I; Imai K; Hinoda Y; Matsuno S; Kudo T
Cancer Immunol Immunother; 2001 Dec; 50(10):539-48. PubMed ID: 11776376
[TBL] [Abstract][Full Text] [Related]
2. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
[TBL] [Abstract][Full Text] [Related]
3. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
4. Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice.
Shinoda M; Kudo T; Suzuki M; Katayose Y; Sakurai N; Saeki H; Kodama H; Fukuhara K; Imai K; Hinoda Y; Matsuno S
Cancer Res; 1998 Jul; 58(13):2838-43. PubMed ID: 9661899
[TBL] [Abstract][Full Text] [Related]
5. Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies.
Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Asano R; Ichiyama M; Imai K; Hinoda Y; Matsuno S; Kudo T
Immunol Lett; 2002 Apr; 81(2):99-106. PubMed ID: 11852114
[TBL] [Abstract][Full Text] [Related]
6. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
7. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.
Riesbeck K; Billström A; Tordsson J; Brodin T; Kristensson K; Dohlsten M
Clin Diagn Lab Immunol; 1998 Sep; 5(5):675-82. PubMed ID: 9729535
[TBL] [Abstract][Full Text] [Related]
8. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M
Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214
[TBL] [Abstract][Full Text] [Related]
9. SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis.
Sakurai N; Kudo T; Suzuki M; Tsumoto K; Takemura S; Kodama H; Ebara S; Teramae A; Katayose Y; Shinoda M; Kurokawa T; Hinoda Y; Imai K; Matsuno S; Kumagai I
Biochem Biophys Res Commun; 1999 Mar; 256(1):223-30. PubMed ID: 10066451
[TBL] [Abstract][Full Text] [Related]
10. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN
Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477
[TBL] [Abstract][Full Text] [Related]
11. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
[TBL] [Abstract][Full Text] [Related]
13. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
[TBL] [Abstract][Full Text] [Related]
14. Antagonistic effects of the staphylococcal enterotoxin a mutant, SEA(F47A/D227A), on psoriasis in the SCID-hu xenogeneic transplantation model.
Boehncke WH; Hardt-Weinelt K; Nilsson H; Wolter M; Dohlsten M; Ochsendorf FR; Kaufmann R; Antonsson P
J Invest Dermatol; 2001 Apr; 116(4):596-601. PubMed ID: 11286628
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered superantigens as tolerable antitumor agents.
Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
[TBL] [Abstract][Full Text] [Related]
16. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells.
Holzer U; Bethge W; Krull F; Ihle J; Handgretinger R; Reisfeld RA; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Immunol Immunother; 1995 Aug; 41(2):129-36. PubMed ID: 7656271
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
18. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity.
Newton DW; Dohlsten M; Olsson C; Segrén S; Lundin KE; Lando PA; Kalland T; Kotb M
J Immunol; 1996 Nov; 157(9):3988-94. PubMed ID: 8892632
[TBL] [Abstract][Full Text] [Related]
20. In vivo anti-MUC1
Pichinuk E; Chalik M; Benhar I; Ginat-Koton R; Ziv R; Smorodinsky NI; Haran G; Garbar C; Bensussan A; Meeker A; Guillaume T; Rubinstein DB; Wreschner DH
Cancer Immunol Immunother; 2020 Jul; 69(7):1337-1352. PubMed ID: 32219500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
